Ads
related to: resmetirom clinical trial for prostate cancer- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Prostate Cancer
Discover Prostate Cancer Treatments
Download our Prostate Cancer Guide
- Schedule an Appointment
Schedule an Appointment Today
Call our Cancer Answer Line
- Second Opinion
gotoper.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist. [1] The most common side effects include diarrhea and nausea. [2] Resmetirom was approved for medical use in the United States in March 2024. [2] [3] [4]
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
The safety and efficacy of piflufolastat (18 F) were evaluated in two prospective clinical trials (trial 1/NCT02981368 and trial 2/NCT03739684) with a total of 593 men with prostate cancer who each received one injection of piflufolastat (18 F).
The programme consisted of three large randomized, double-blind, placebo-controlled trials in which a total of 8,113 men with localized or locally advanced prostate cancer were treated with 150 mg/day bicalutamide plus standard care (watchful waiting, radical prostatectomy, or radiation therapy) (n=4052) or given placebo (standard care alone ...
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
Ads
related to: resmetirom clinical trial for prostate cancergotoper.com has been visited by 10K+ users in the past month